Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 trial in resected Stage II-III KRAS G12C-positive non-small cell lung cancer compares Divarasib with investigator's choice of immunotherapy or observa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Divarasib

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING